Back to search page

TRKR20180723001

Pharmaceutical compositions that act as adenosine receptor antagonist which cures liver diseases, such as Nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis of liver containing adenosine derivatives

TECHNOLOGY PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

A bio-venture Korean SME has developed first-in-class drug synthesis since established in 2015, and the company represents new drug candidates that have an efficiency of relief on Nonalcoholic Steatohepatitis, Liver Fibrosis, and Liver Cirrhosis, which are called Adenosine Receptor Antagonist. The company came up with the idea due to lack of pharmaceutical treatment for NASH. The company is, thus, open to take the partnership of license and commercial agreement with technical assistant.


FULL DESCRIPTION

A Korean company established in 2015 is based on research of pharmaceutical products and drugs.

Nonalcoholic fatty liver disease (NAFLD) is caused by obesity and diabetes, and it includes simple steatosis, Nonalcoholic Steatohepatitis (NASH) along with liver cell disruption, inflammation, and fibrosis, and Cirrhosis of liver.

There is approximately 20~30% of population suffering from NAFLD due to geriatric diseases, and NASH is caused approximately 10~20% of NAFLD patients, and 9~25% of them suffers from liver cirrhosis and liver cancer eventually.
Not all of patients has NASH, however in case of causing it, it results in death due to complication. Therefore, there is point that stage of NASH has to be cured for NAFLD.

The existing new drug candidate materials have 72% and 85% of sequence homology to humanís receptors in case of rat and sheep respectively, which shows a low rate of receptors. In spite of excellent results of animal test on new drug materials, it could not be examined the same result on clinical trial. However, the company examined the equal binding affinity with human regardless of species.

The company is looking for partners who would solve the problems on the existing materials and develop new treatment for non-alcoholic steatohepatitis and make them sued in pharmaceutical industry under commercial agreement with technical assistance and license agreement.


Partner expertise sought:

- Type of partner sought: The Korean company is seeking for the experts as the partners in order to collaborate on the work of developing new drug candidates as a treatment for non-alcoholic fatty liver diseases. The technology is highly specific and detailed, so the partners should have capabilities of studying the pharmaceutical products and drugs.
- Specific area of activity of the partner: - Type of partner sought: Companies have professional perspectives on pharmaceutical materials.

- Specific area of activity of the partner: The partners should be specialized in the industry of pharmaceutical, and also interested in developing new drug candidates.

- Task to be performed: The company has on-going research of pharmaceutical products and drugs related to non-alcoholic liver diseases, and they would like to focus on developing new medication under commercial agreement with technical assistant, and license agreement would make the new developed drugs be used in pharmaceutical industry.


IPR:

Patents granted

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
SOUTH KOREA
Profile date
26/11/2018
Deadline
27/11/2019

PARTNERSHIP(S) SOUGHT

License agreement Commercial agreement with technical assistance

CLASSIFICATIONS

INDUSTRY SECTORS
Life Sciences \ Biosciences and Health \ Drug Discovery and Drug Development
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs
COMMERCIAL KEYWORDS
none...
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Other Medical/Health Related / Pharmaceuticals/fine chemicals

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number TRKR20180723001